Hani Luxenburg - Mediwound Chief Officer
| MDWD Stock | USD 16.48 0.28 1.67% |
Executive
Hani Luxenburg is Chief Officer of Mediwound
| Age | 51 |
| Address | 42 Hayarkon Street, Yavne, Israel, 8122745 |
| Phone | 972 7 797 14100 |
| Web | https://www.mediwound.com |
Mediwound Management Efficiency
The company has return on total asset (ROA) of (0.1577) % which means that it has lost $0.1577 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7566) %, meaning that it created substantial loss on money invested by shareholders. Mediwound's management efficiency ratios could be used to measure how well Mediwound manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.11. In addition to that, Return On Capital Employed is expected to decline to -0.29. At present, Mediwound's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.30, whereas Other Assets are forecasted to decline to about 311.2 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Theresa Lavallee | Coherus BioSciences | 58 | |
| Paul Reider | Coherus BioSciences | 54 | |
| Robert MD | Lyra Therapeutics | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Jami Taylor | Coherus BioSciences | N/A | |
| Cheston Turbyfill | Coherus BioSciences | N/A | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| MRCP MD | Coherus BioSciences | 55 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| Scott Saywell | Coherus BioSciences | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Roman Necina | Hookipa Pharma | 56 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| MD MBA | SAB Biotherapeutics | 51 | |
| Ronan JD | Lyra Therapeutics | 51 | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.16 |
Mediwound Leadership Team
Elected by the shareholders, the Mediwound's board of directors comprises two types of representatives: Mediwound inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mediwound. The board's role is to monitor Mediwound's management team and ensure that shareholders' interests are well served. Mediwound's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mediwound's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Ex Director | ||
| Ofer BSc, Chief Officer | ||
| Lior MD, CoFounder | ||
| Yaron Adv, General VP | ||
| Hani Luxenburg, Chief Officer | ||
| CWS DPM, Chief Officer | ||
| Shmulik Hess, COO Officer | ||
| Ety Klinger, Chief Officer | ||
| Liron Gal, Executive Technology | ||
| Barry Wolfenson, Executive Development | ||
| Pr MD, CoFounder Director | ||
| Ety MBA, Chief Officer |
Mediwound Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mediwound a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 157.98 M | ||||
| Shares Outstanding | 10.79 M | ||||
| Shares Owned By Insiders | 19.75 % | ||||
| Shares Owned By Institutions | 45.50 % | ||||
| Number Of Shares Shorted | 593.04 K | ||||
| Price To Earning | 16.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Mediwound is a strong investment it is important to analyze Mediwound's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mediwound's future performance. For an informed investment choice regarding Mediwound Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mediwound. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Mediwound Stock refer to our How to Trade Mediwound Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mediwound. If investors know Mediwound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mediwound listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share 2.18 | Quarterly Revenue Growth 0.061 | Return On Assets (0.16) | Return On Equity (0.76) |
The market value of Mediwound is measured differently than its book value, which is the value of Mediwound that is recorded on the company's balance sheet. Investors also form their own opinion of Mediwound's value that differs from its market value or its book value, called intrinsic value, which is Mediwound's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mediwound's market value can be influenced by many factors that don't directly affect Mediwound's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mediwound's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mediwound is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mediwound's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.